Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides

Launched by ACADEMISCH MEDISCH CENTRUM - UNIVERSITEIT VAN AMSTERDAM (AMC-UVA) · Jun 3, 2024

Keywords

ClinConnect Summary

This clinical trial is designed to compare the effectiveness and safety of five different products that use Botulinum Neurotoxin Type A (commonly known as Botox) for treating frown lines, which are the wrinkles that appear between your eyebrows. The study aims to find out which product works best and lasts the longest while also looking at any possible side effects. Women aged 18 and older with moderate to severe frown lines can participate if they meet certain health criteria.

Participants will receive injections of one of the Botulinum products and will take weekly photos to track changes in their frown lines. They will also fill out questionnaires before and after the study to share their experiences and satisfaction with the treatment. This research is important because it will help doctors understand which Botox product might be the best option for their patients, ultimately leading to better treatment choices and improved results for those looking to reduce frown lines.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Women aged 18 years or over, with moderate to severe glabellar lines
• • Willing to provide written informed consent
• • American Society of Anesthesiologists (ASA) Physical Status Classification 1 or 2
• Exclusion Criteria:
• • ASA Classification 3 or over
• • History of hypersensitivity or adverse reactions to botulinum toxin or any of its components
• • Infection at the injection site
• • Previous treatment with botulinum toxin (lifetime)
• • Pregnant or breastfeeding women
• • Neuromuscular disorders or conditions that could interfere with the study assessments